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Introduction
Cognitive impairment impacts roughly 50% of the 
patients with multiple sclerosis (MS), and cogni-
tive processing speed is the most frequently affected 
domain.1 Cognitive impairment in MS correlates 
strongly with magnetic resonance imaging (MRI) 
measures of lesion burden2 and brain atrophy3 and 
affects occupational, social, and psychological 
functioning.4 Thus, prevention of the development 
or worsening of cognitive decline is a therapeutic 
goal in MS.
Several studies examined the effect of MS disease-
modifying therapies on neuropsychological tests.5–11 
Some of these studies were observational, such as 
Cognitive Impairment in Multiple Sclerosis, in which 
patients with relapsing–remitting multiple sclerosis 
(RRMS) initiating treatment with interferon (IFN) 
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Objective: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on 
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beta were administered a battery of neuropsychologi-
cal tests once yearly.8 In patients treated with subcuta-
neous (SC) IFN beta-1a, risk of cognitive impairment 
was significantly reduced following 3 years of treat-
ment with 44 µg compared with 22 µg dosing.8 Only a 
few randomized, placebo-controlled phase III trials 
included neuropsychological tests.5,12–15 In the 
Natalizumab Safety and Efficacy in Relapsing-
Remitting Multiple Sclerosis (AFFIRM) study. 
Natalizumab significantly reduced the risk of con-
firmed progression of cognitive deficits compared 
with placebo, based on 0.5 standard deviation (SD) 
change on the 3-Second Paced Auditory Serial 
Addition Test (PASAT-3) sustained for 12 weeks.11 In 
SENTINEL, there was no significant PASAT-3 
effect of natalizumab co-administered with intramus-
cular (IM) IFN beta-1a compared with placebo 
co-administered with IM IFN beta-1a.11 In a pooled 
analysis of FREEDOMS and FREEDOMS II, fingoli-
mod (0.5 mg) demonstrated a significant benefit com-
pared with placebo on change from baseline in PASAT 
scores after 6 months of treatment.16 Finally, in the 
Multiple Sclerosis Collaborative Research Group 
trial, IM IFN beta-1a demonstrated a significant 
benefit compared with placebo over 2 years on a com-
posite multi-domain neuropsychological test battery.5
Daclizumab beta (formerly daclizumab high-yield 
process, approved as ZINBRYTA®, which has a dif-
ferent form and structure than an earlier form of 
daclizumab) is a humanized monoclonal antibody 
against the interleukin 2 (IL-2) receptor alpha 
subunit (CD25).17 In the randomized, double-blind, 
active-controlled, phase III DECIDE study, dacli-
zumab beta 150 mg SC every 4 weeks showed supe-
rior efficacy on relapses, MRI outcomes, and 
24-week confirmed disability progression compared 
with IFN beta-1a 30 µg IM once weekly over 96–
144 weeks of treatment in patients with RRMS.18 
Cognitive outcomes were assessed using PASAT-3 
as well as the Symbol Digit Modalities Test 
(SDMT),19 a less frequently used but highly sensi-
tive20 and promising measure of cognitive process-
ing speed in the visual modality. On both instruments, 
there was evidence for a benefit of daclizumab beta 
versus IM IFN beta-1a at week 96. As reported pre-
viously,18 the increase from baseline in the PASAT-3 
composite z-score was significantly different in 
daclizumab beta–treated patients (median (inter-
quartile range), 0.177 (0.088, 0.530)) compared 
with IM IFN beta-1a–treated patients (0.177 (0.088, 
0.442); p = 0.04) using an analysis of covariance 
model based on ranks, a non-parametric test that 
tests on a difference in the distribution and not 
solely on a difference in the means or medians.21 
Similarly, mean (SD) improvement from baseline in 
SDMT scores was significantly greater in dacli-
zumab beta–treated patients (4.1 (12.4)) compared 
with IM IFN beta-1a–treated patients (2.9 [12.7]; 
p = 0.0274).18
Cutoffs to evaluate clinically meaningful change on 
the PASAT have not been established,22 although 
0.5 SD change on the PASAT-3 has been used as a 
non-clinically validated endpoint in some studies.11 
The SDMT does have proposed benchmarks for 
clinically meaningful change that are anchored to 
functional points of reference in the real-world 
setting, allowing for a richer analysis of responders 
and deteriorating cognitive status. A decline of 3–4 
points in mean SDMT scores has been tied to mental 
status change during MS relapse as observed by 
patients, caregivers, or clinicians,23 as well as decline 
in vocational status as defined by reduction in work 
responsibilities, early retirement, and/or receipt of 
disability benefits.22
Herein, we report an expanded analysis of the effects 
of daclizumab beta on cognitive processing speed as 
measured by the SDMT, examining the time course 
of improvement from baseline in SDMT scores—
including effects at week 144—as well as odds of 
clinically meaningful change (3-point or 4-point 
change in SDMT score).
Method
Patients and study design
As described previously,18 DECIDE (ClinicalTrials.
gov identifier NCT01064401) enrolled patients with 
RRMS24 18–55 years of age, with Expanded Disability 
Status Scale (EDSS) score25 0–5.0, and one of the fol-
lowing: two or more clinical relapses within the pre-
vious 3 years, including at least one clinical relapse 
within 1 year prior to randomization, or one or more 
clinical relapse and one or more new lesion on MRI 
that was not associated with the clinical relapse within 
the previous 2 years, with at least one of these events 
occurring within 1 year prior to randomization. 
Exclusion criteria included MS relapse within 50 days 
prior to randomization; treatment with mitoxantrone, 
cyclophosphamide, fingolimod, or natalizumab 
within 1 year prior to randomization; or treatment 
with intravenous or oral corticosteroids or glatiramer 
acetate within 30 days prior to randomization.
Patients were randomized 1:1 to receive daclizumab 
beta 150 mg SC every 4 weeks and IM placebo once 
weekly or IM IFN beta-1a 30 µg once weekly and SC 
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placebo every 4 weeks for at least 96 weeks and no 
more than 144 weeks. The study was designed to end 
when the last enrolled patient completed the week 96 
visit. Study visits occurred every 4 weeks and included 
clinical and safety assessments. Patients who perma-
nently discontinued study treatment before week 140 
had the option to initiate treatment with an approved 
open-label alternative MS medication. Changes from 
baseline to weeks 48 and 96 in SDMT and PASAT-3 
scores were tertiary endpoints in the study.
All patients provided written informed consent. The 
study was approved by relevant central and local eth-
ics committees and was conducted in accordance with 
the International Conference on Harmonisation 
Guidelines for Good Clinical Practice and the princi-
ples of the Declaration of Helsinki.
SDMT
The oral response version of the SDMT was adminis-
tered at baseline and at 24-week intervals thereafter. 
As described in prior MS studies,20,26,27 the SDMT19 
presents a key consisting of nine abstract symbols 
paired with numbers ranging from 1 to 9 and a test 
consisting of a 120-item sequence (10 for learning) of 
abstract symbols presented in random order. Patients 
are asked to associate the symbols with the corre-
sponding numbers as shown in the key, responding 
orally as quickly as possible. The number of correct 
responses (out of a maximum of 110) in 90 seconds 
was recorded, with higher scores indicating better 
performance.
Statistical analysis
The analyses were performed on data from the inten-
tion-to-treat (ITT) population, defined as all rand-
omized patients who received at least one dose of 
study treatment. Patients with missing data for base-
line covariates and observed data after patients 
switched to alternative MS medications were 
excluded.
Two approaches were used to analyze change from 
baseline on the SDMT. The statistical analysis plan 
specified that the data would be analyzed using an 
analysis of covariance model on the change from 
baseline after imputing missing data using a last 
observation carried forward (LOCF) approach. 
However, because the dropout rate in the IM IFN 
beta-1a group was higher earlier in the treatment 
period, the imputation method using LOCF was sus-
ceptible to bias; therefore, a post hoc analysis using a 
linear mixed model also was used and is presented 
here.28 In this model, a likelihood-based method was 
used to estimate the treatment effect, and no explicit 
imputation on the missing data was performed. The 
analysis included observed data up to either the end 
of the study or use of alternative MS medication. 
Treatment was included as the fixed effect and indi-
vidual specific time (visit) and intercept were included 
as random effects. Interaction terms were treatment 
and time, adjusting for baseline SDMT score, prior 
IFN beta use (yes, no) and baseline age (⩽35, 
>35 years). Treatment differences at each study visit 
were estimated from this model.
Patients were classified into three groups (worsened, 
stable, or improved) at week 96 based on validated 
thresholds for clinically meaningful change on the 
SDMT (3-point or 4-point changes from baseline).22,23 
For the 3-point threshold, worsening was defined as a 
change of ⩽−3 points, stability was defined as a 
change of >−3 points and <3 points, and improvement 
was defined as a change of ⩾3 points. For the 4-point 
threshold, worsening was defined as a change of ⩽−4 
points, stability was defined as a change of >−4 points 
and <4 points, and improvement was defined as a 
change of ⩾4 points).
Treatment differences in the proportion of patients 
with SDMT worsening (yes vs no) were evaluated 
post hoc based on a generalized estimating equations 
(GEE) approach with a logistic model. The analysis 
was repeated to evaluate treatment differences in the 
proportion of patients with SDMT improvement. In 
addition, a repeated measures ordinal regression 
model using the GEE approach was also evaluated to 
compare changes in SDMT when categorized as 
worsened, stable, or improved. Models included treat-
ment group, time, and treatment by time interaction, 
adjusting for baseline SDMT score, prior IFN beta 
use (yes, no), and baseline age (⩽35, >35 years). An 
unstructured working correlation matrix was used.
Results
Descriptive data
A total of 1841 patients were randomized (daclizumab 
beta, n = 919; IM IFN beta-1a, n = 922). All were 
included in the ITT population. Demographic and 
baseline MS disease characteristics were well bal-
anced across treatment groups, as reported previ-
ously.18 At baseline, in the daclizumab beta and IM 
IFN beta-1a groups, mean (SD) SDMT score was 
48.5 (15.9) and 47.7 (16.1), respectively, and median 
(range) SDMT score was 49 (0–110) and 49 (3–110), 
respectively.
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Group effects on SDMT
Based on the linear mixed model analysis approach, 
there was a significant group × time interaction 
(p = 0.0004). Significantly greater mean improvement 
from baseline in SDMT scores was observed with 
daclizumab beta compared with IM IFN beta-1a at 
week 96 (mean (SD) change from baseline: 4.1 (12.4) 
vs 2.9 (12.7); p = 0.0274), as reported previously 
(Figure 1).18 This effect was sustained at week 144 
(6.3 (12.6) vs 3.1 (13.2); p = 0.0024) in a limited num-
ber of patients completing 144 weeks of treatment 
with available SDMT scores (daclizumab beta, 
n = 287; IM IFN beta-1a, n = 277).
Clinically meaningful change and responder 
analyses
In the GEE analysis, significantly more patients 
treated with daclizumab beta compared with IM IFN 
beta-1a showed clinically meaningful improvement, 
defined as a ⩾3-point increase on the SDMT, at week 
96 (60.0% vs 54.1%; odds ratio (OR; 95% confidence 
interval, CI): 1.30 (1.05–1.62); p = 0.0153) and week 
144 (65.5% vs 52.0%; OR (95% CI): 1.60 (1.18–
2.19); p = 0.0028; Figure 2(a)). Similarly, significantly 
more patients treated with daclizumab beta showed a 
⩾4-point increase at week 96 (55.4% vs 50.1%; OR 
(95% CI): 1.26 (1.01–1.56); p = 0.0366) and week 144 
(61.7% vs 48.4%; OR (95% CI): 1.53 (1.12–2.07); 
p = 0.0067; Figure 2(b)).
Significantly fewer patients treated with daclizumab 
beta versus IM IFN beta-1a showed clinically mean-
ingful worsening, defined as a ⩾3-point decrease on 
the SDMT at week 96 (19.4% vs 24.8%; OR (95% 
CI): 0.72 (0.56–0.92); p = 0.0103; Figure 3(a)). There 
was a trend for significance at week 144 (18.8% vs 
26.4%; OR (95% CI): 0.72 (0.50–1.03); p = 0.0754). 
When clinically meaningful worsening was defined 
as a ⩾4-point decrease, there was a trend for signifi-
cance at week 96 (17.5% vs 21.1%; OR: 0.78 (95% 
CI: 0.60–1.02); p = 0.0645) and no significant differ-
ence between daclizumab beta and IM IFN beta-1a at 
week 144 (17.1% vs 23.5%; OR: 0.77 (95% CI: 0.53–
1.12); p = 0.1719; Figure 3(b)).
Based on the 3-point threshold, the percentage of patients 
exhibiting worsening, stability, and improvement at 
week 96 was 19.4%, 20.6%, and 60.0%, respectively, in 
the daclizumab beta group and 24.8%, 21.1%, and 
54.1%, respectively, in the IM IFN beta-1a group (Figure 
4(a)). Based on the 4-point threshold, the percentage of 
patients exhibiting worsening, stability, and improve-
ment at week 96 was 17.5%, 27.1%, and 55.4%, respec-
tively, in the daclizumab beta group and 21.1%, 28.7%, 
and 50.1%, respectively, in the IM IFN beta-1a group 
(Figure 4(b)). The OR (95% CI) for worsening and 
worsening or stable SDMT scores for daclizumab beta 
compared with IM IFN beta-1a was 0.75 (0.61–0.93; 
p = 0.0088) for the 3-point threshold and 0.79 (0.64–
0.97; p = 0.0267) for the 4-point threshold.
Figure 1. Mean change from baseline in Symbol Digit Modalities Test (SDMT) score at weeks 24, 48, 72, 96, and 
144. Patients with available data for baseline covariates were included. Analyses were based on observed data with no 
imputation for missing data. IFN: interferon; IM: intramuscular; SD: standard deviation.
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Discussion
Although cognitive deficits associated with MS are 
well-documented and contribute to functional disabil-
ity and diminished quality of life,4 relatively little is 
known about the effect of MS therapeutics on cogni-
tive function. Even less is understood about treatment 
effects on the SDMT, a promising and increasingly 
touted1 measure of cognitive processing speed that 
is accepted by patients and could be easily applied 
in a large phase III trial. The SDMT also has the 
advantage of proposed benchmarks for clinically 
meaningful change in test performance, most notably 
a 3-point to 4-point or greater change in scores.22,23 
Here, we report that daclizumab beta showed signifi-
cantly greater benefits on the SDMT compared with 
IM IFN beta-1a over 96–144 weeks in a large cohort 
of patients with RRMS in the randomized double-
blind phase III DECIDE study.18
As reported previously, mean improvement from 
baseline in SDMT scores was significantly greater in 
daclizumab beta–treated patients compared with IM 
Figure 2. Percentage of patients with (a) ⩾3-point improvement or (b) ⩾4-point improvement in Symbol Digit 
Modalities Test score at weeks 24, 48, 72, 96, and 144. Patients with available data for baseline covariates were included. 
Analyses were based on observed data with no imputation for missing data. IFN: interferon; IM: intramuscular.
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IFN beta-1a–treated patients at week 96.18 Although 
not part of our primary discussion because of the 
much smaller number of patients at week 144 and 
concerns for selection bias, the superiority of dacli-
zumab beta over IM IFN beta-1a appeared to persist 
at week 144. Using the 3-point responder definition, 
the odds of clinically meaningful improvement on 
the SDMT were significantly higher with dacli-
zumab beta compared with IM IFN beta-1a at weeks 
96 and 144, and the odds of clinically meaningful 
worsening were significantly lower at weeks 24, 72, 
and 96. Using the 4-point responder definition, the 
odds of clinically meaningful improvement on the 
SDMT were significantly higher with daclizumab 
beta compared with IM IFN beta-1a at weeks 96 and 
144, and the odds of clinically meaningful worsen-
ing were significantly lower at week 24. These 
results provide evidence of not only a statistically 
significant benefit of daclizumab beta compared 
with IM IFN beta-1a in raw SDMT scores but also a 
clinically meaningful benefit in performance tied to 
a measurable functional deficit, highlighting the 
Figure 3. Percentage of patients with (a) ⩾3-point decline or (b) ⩾4-point decline in Symbol Digit Modalities Test score 
at weeks 24, 48, 72, 96, and 144. Patients with available data for baseline covariates were included. Analyses were based 
on observed data with no imputation for missing data. IFN: interferon; IM: intramuscular.
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importance of these findings from a clinical 
perspective.22,23
It is interesting that there was greater observed reduc-
tion in relapses in the daclizumab beta group com-
pared with the IM IFN beta-1a group by 12 weeks in 
DECIDE,18 while the statistically significant effect on 
the SDMT occurred much later, at the 96-week time 
point. A delay between reduced inflammatory activity 
and benefits as measured on a neuroperformance scale 
such as the SDMT may be related to the time neces-
sary for tissue repair, possibly including partial remy-
elination, neuronal functional recovery, synaptic 
reconstitution, and so on. Furthermore, the time course 
of these functional reparative events might reflect the 
volume of inflamed brain tissue and the locations of 
the active area of inflammation responding to dacli-
zumab therapy. Over the course of 2–3 years, these 
anti-inflammatory and remyelination effects could 
conceivably protect against neurodegeneration. SDMT 
Figure 4. Percentage of patients with worsened, stable, or improved Symbol Digit Modalities Test score at week 96 
using (a) a 3-point threshold or (b) a 4-point threshold. Patients with available data for baseline covariates were included. 
Analyses were based on observed data with no imputation for missing data. CI: confidence interval; IFN: interferon;  
IM: intramuscular; OR: odds ratio.
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is robustly correlated with deep gray matter volume in 
MS,29,30 and recently, changes in SDMT over 3 years 
were found to be correlated with preserved morphol-
ogy of the anterior and dorsal aspects of the thala-
mus.31 It remains to be seen how changes in SDMT 
correlate with MRI variables in this phase III study.
The positive changes in SDMT scores seen in our 
study represent small, if statistically significant 
effects. By comparison, the magnitude of improve-
ment was much larger in a retrospective analysis of 
SDMT when used to screen for progressive multifo-
cal leukoencephalopathy during the reintroduction of 
natalizumab (STRATA).32 The studies differ in many 
respects, not the least of which is that herein SDMT 
was administered every 24 weeks, whereas in 
STRATA, patients took the test every 4 weeks. 
STRATA was also an uncontrolled open-label exten-
sion study in which patients had been receiving ther-
apy for a duration longer than 96 weeks. Furthermore, 
the primary purpose of the retrospective analysis of 
the STRATA neuropsychology data was to assess the 
reliability of monthly administrations of SDMT and 
the MS Neuropsychological Questionnaire33 over a 
48-week period. Frequent administrations of the 
SDMT are suitable to assess reliability but may not be 
suitable to evaluate treatment effects, as practice and 
training effects would be magnified with monthly 
administrations of the SDMT.34 The difference in 
practice effect between monthly versus 24-week 
intervals is unknown and may explain this differ-
ence.18,32 Moreover, practice and training effects were 
controlled for in DECIDE through the use of a two-
arm design to answer the question of relative effects 
between two treatments.
There are several limitations of this analysis that 
must be taken into consideration when interpreting 
the results. First, DECIDE was not powered to study 
the effects of daclizumab beta on cognitive function; 
the primary and secondary objectives of the study 
were to examine the effect of daclizumab beta on 
clinical endpoints (relapse and disability progres-
sion) and MRI endpoints (number of new or newly 
enlarging T2-hyperintense lesions).18 That said, the 
large sample size was more than adequate to deter-
mine a small but reliable effect. Second, the linear 
mixed-model approach used to analyze change from 
baseline in SDMT score28 was not pre-planned and 
was used because it is less sensitive to bias related to 
unequal dropout rates in the treatment groups. Third, 
although the result at week 144 appears to substanti-
ate the findings of the pre-planned 96-week tertiary 
outcome analysis, only a small subset of patients 
completed 144 weeks of treatment due to study 
design (i.e. because the end of study visit occurred 
for each patient either at week 144 or when the last 
patient enrolled had completed the week 96 visit, 
whichever was sooner), thereby introducing the 
potential for selection bias. Finally, the SDMT does 
not provide an exhaustive assessment of cognitive 
function; rather, it is used to assess a relatively nar-
row range of cognitive ability, even if processing 
speed impairment is known to be very relevant to dis-
ability in MS. The effects of daclizumab beta on 
SDMT scores at week 96 are complemented by a 
similar effect on the PASAT-3,18 but a fuller under-
standing of the impact of daclizumab beta treatment 
on cognitive function in patients with RRMS requires 
a more comprehensive test battery.
In summary, daclizumab beta demonstrated a benefit 
on one sphere of cognitive function as measured by 
the SDMT. In addition to improvements in traditional 
MS clinical and MRI outcomes,18 these findings sug-
gest that daclizumab beta provides superior benefits 
over IM IFN beta-1a on cognitive outcomes, which 
may increase over time. These benefits may have 
implications for patients’ psychological, social, and 
occupational functioning and may contribute to 
improved quality of life.
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